# A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct05009069/  
OnCo record `nct05009069` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Capecitabine, Fluorouracil, Atezolizumab in colorectal cancer, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT05009069 by Hoffmann-La Roche, with 58 participants enrolled, started 2022-03-18 and due to reach its primary completion in 2023-11-21. Interventions recorded: Radiotherapy, Capecitabine, Fluorouracil, Atezolizumab, Tiragolumab. Conditions listed: Rectal Neoplasms, Rectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05009069
- Phase: 2
- Setting: A Phase II, Randomized, Open Label, Parallel-group Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
- Sponsor: Hoffmann-La Roche
- Enrolled: 58

## Sources

- ClinicalTrials.gov NCT05009069: https://clinicaltrials.gov/study/NCT05009069

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct05009069.json